H.C. Wainwright Reiterates Buy Rating on Ultragenyx Pharma (RARE)

August 20, 2026 6:56 AM

H.C. Wainwright analyst Ed Arce reiterated a Buy rating and $50.00 price target on Ultragenyx Pharma (NASDAQ: RARE).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found